Familial abnormalities of endocannabinoid signaling in schizophrenia

Oleoylethanolamide and Human Neural Responses to Food Stimuli in Obesity

(2014) Martin Grosshans et al.   JAMA Psychiatry

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the “Mirror Effect” of Schizophrenia

(2012) Joëlle Desfossés et al.   Frontiers in Psychiatry

Dysfunctional Brain Networks and Genetic Risk for Schizophrenia: Specific Neurotransmitter Systems

(2010) Jussi Hirvonen et al.   CNS Neuroscience & Therapeutics

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

(2009) Dagmar Koethe et al.   BRITISH JOURNAL OF PSYCHIATRY

Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid

(2009) Dagmar Koethe et al.   JOURNAL OF NEURAL TRANSMISSION

Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study

(2009) Paul Lichtenstein et al.   LANCET

Heritability of Changes in Brain Volume Over Time in Twin Pairs Discordant for Schizophrenia

(2008) Rachel G. H. Brans et al.   ARCHIVES OF GENERAL PSYCHIATRY

Hypothalamus volume in twin pairs discordant for schizophrenia

(2008) P. Cédric M.P. Koolschijn et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy

(2008) Stéphane Potvin et al.   JOURNAL OF PSYCHOPHARMACOLOGY